论文部分内容阅读
目的:阿托伐他汀对ST段抬高心肌梗死患者血清CRP、IL-6的作用及意义。方法:选择诊断为ST段抬高心肌梗死患者134例,随机分为对照组和实验组,各67例,均给予阿司匹林、减轻心脏耗氧等常规治疗,实验组除标准治疗外,入院给予每晚睡前口服阿托伐他汀40mg,检测2组治疗前及8周后血清C反应蛋白(CRP)、IL-6、血脂的变化。结果:治疗后对照组血脂、血清CRP、IL-6无明显变化,而实验组总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、血清CRP及IL-6明显降低(P<0.05)。结论:阿托伐他汀除具有降脂作用外,还具有降低炎症反应,有利于ST段抬高的急性心肌梗死(STEAMI)患者的恢复;降低CRP的作用可能是通过降低IL-6实现的。
AIM: To investigate the effect of atorvastatin on serum CRP and IL-6 levels in patients with ST-elevation myocardial infarction. Methods: One hundred and sixty-four patients with ST-segment elevation myocardial infarction were selected and randomly divided into control group and experimental group, each with 67 cases. All patients were given aspirin to relieve heart oxygen consumption. In addition to standard treatment, Atorvastatin 40 mg orally before going to sleep, test two groups before and after 8 weeks of serum C-reactive protein (CRP), IL-6, blood lipid changes. Results: There was no significant change in serum lipids, serum CRP and IL-6 in the control group after treatment, while the total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), serum CRP and IL- ). Conclusion: Atorvastatin, in addition to its lipid-lowering effect, has the effect of reducing inflammation and recovering patients with ST-elevation acute myocardial infarction (STEAMI). The effect of reducing CRP may be through decreasing IL-6.